Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 aggregate principal amount of its 1.47% Senior Notes due June 17, 2030 (the “Notes,” such term to include any notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $50,000,000 aggregate principal amount of its 1.477.75% Senior Secured Notes due June September 17, 2030 2017 (as amended, restated, supplemented or otherwise modified from time to time, the “Notes,” ”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. A. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Section”, “Schedule” or an “Exhibit” are, unless otherwise specified, to a Section, Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $50,000,000 aggregate principal amount of its 1.477.86% Senior Notes due June 17August 1, 2030 2011 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 13)13 of this Agreement. The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 US$25,000,000.00 aggregate principal amount of its 1.47% Senior Secured Notes due June 17July 25, 2030 2009 (the “"Notes,” ", such term to include any such notes issued in substitution therefor therefore pursuant to Section 1314 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $30,000,000 aggregate principal amount of its 1.477.54% Senior Notes due June 17September 1, 2030 2007 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $50,000,000 aggregate principal amount of its 1.474.48% Senior Notes due June 17December 13, 2030 2009 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $25,000,000 aggregate principal amount of its 1.477.93% Senior Notes due June 17December 27, 2030 2004 (the “"Notes,” " such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $35,000,000 aggregate principal amount of its 1.477.463% Senior Notes due June 17October 31, 2030 2006 (the “Notes,” "NOTES", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $50,000,000 aggregate principal amount of its 1.477.27% Senior Notes due June 17Notes, 2030 Due 2009 (the “Notes,” "NOTES", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of €125,000,000 $569,000,000 aggregate principal amount of its 1.475.22% Senior Notes due June 17August 9, 2030 2020 (the “Notes,” ”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall will be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $20,000,000 aggregate principal amount of its 1.476.09% Senior Notes due June 17December 20, 2030 2012 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $30,000,000 aggregate principal amount of its 1.476.86% Senior Notes due June 17September 1, 2030 2015 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue issuance and sale of €125,000,000 $14,950,000 aggregate principal amount of its 1.4713.75% Senior Notes due June 17, 2030 2026 (the “Notes,” such term to include any notes issued in substitution therefor ”) pursuant to Section 13this Note Exchange Agreement (this “Agreement”). The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule BA; and references to an “Annex,” a “Schedule” or an “Exhibit” are, unless otherwise specified, to an Annex, a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $60,000,000 aggregate principal amount of its 1.474.77% Senior Notes due June 17March 15, 2030 2014 (the “"Notes,” " such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 up to $5,000,000 aggregate principal amount of its 1.47% Senior Secured Notes due June 17May 1, 2030 2008 (the “Notes,” ”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved in writing by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $60,000,000 aggregate principal amount of its 1.477.59% Senior Notes due June 17in October 1, 2030 2010 (the “Notes,” "NOTES", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if it any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of €125,000,000 $150,000,000 aggregate principal amount of its 1.475.24% Senior Notes due June 17April 29, 2030 2011 (the “Notes,” ”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $7,000,000 aggregate principal amount of its 1.47% Senior Unsecured Notes due June 17December 29, 2030 2006 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1314 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue issuance and sale of €125,000,000 $85,800,000 aggregate principal amount of its 1.475.03% Senior Notes due June 17July 19, 2030 2024 (as amended, restated, supplemented or otherwise modified from time to time, the “Notes,” ”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $50,000,000 aggregate principal amount of its 1.473.15% Senior Notes due June 17April 15, 2030 2028 (the “Notes,” such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue issuance and sale of €125,000,000 up to $1,500,000 aggregate principal amount of its 1.4710% Senior Secured Convertible Notes due June 17July 31, 2030 1995 (the “Notes,” "NOTES", such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall section 12) to be substantially in the form of the Notes set out in Exhibit 1A, with such changes --------- therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule Bsection 13; and references to a “"Schedule” " or an “"Exhibit” are, " are unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $100,000,000 aggregate principal amount of its 1.474.19% Senior Guaranteed Notes due June 17September 20, 2030 2029 (the “Notes,” ”), such term to include any such notes issued in substitution therefor therefore pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €$125,000,000 aggregate principal amount of its 1.475.60% Senior Notes due June 17May 15, 2030 2018 (the “Notes,” such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $75,000,000 aggregate principal amount of its 1.473.68% Senior Notes due June 17November 15, 2030 2025 (the “Notes,” ”, such term to include any such notes as amended, restated or otherwise modified from time to time pursuant to Section 17 and any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €$125,000,000 aggregate principal amount of its 1.474.47% Senior Guaranteed Notes due June 17October 30, 2030 2031 (the “Notes,” ”, such term to include any such notes issued in substitution therefor therefore pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, 1 with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 U.S. $400,000,000 aggregate principal amount of its 1.47% Senior Subordinated Notes due June 17January 27, 2030 2010 (the “Notes,” "NOTES", such term to include any such notes issued in substitution therefor pursuant to Section 1311 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. 2.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $100,000,000 aggregate principal amount of its 1.477.49% Senior Notes due June 17November 30, 2030 2006 (the “"Notes,” " such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $2,020,000 aggregate principal amount of its 1.47% Increasing Rate Senior Secured Notes due June 17May 26, 2030 2008 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved in writing by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $11,000,000 aggregate principal amount of its 1.477% Senior Notes due June 17December 31, 2030 2023 (the “Notes,” ”, such term to include any such notes issued in substitution therefor pursuant to Section 1311). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as . The outstanding principal amount of the Notes may be approved by increased if the Purchasers and Company elects to pay interest in kind as set forth in the CompanyNotes. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $15,000,000 aggregate principal amount of its 1.476.90% Senior Secured Notes due June 17, 2030 2010 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of €125,000,000 $37,500,000 aggregate principal amount of its 1.4712% Senior Secured Notes due June 17[_________], 2030 2001 (the “"Notes,” ", such term to include any such notes issued in substitution therefor pursuant to Section 1314 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue issuance and sale of €125,000,000 $250,000,000 aggregate principal amount of its 1.474.31% Senior Secured Notes due June 172024 (as amended, 2030 (restated, supplemented or otherwise modified from time to time, the “Notes,” ”, such term to include any such notes issued in substitution therefor pursuant to Section 1314). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.